• Most Popular
  • Most Shared

EU seeks lung cancer caution on Pfizer's Exubera

Tue Jun 17, 2008 12:05pm EDT

Stocks

   

LONDON, June 17 (Reuters) - The European Medicines Agency said on Tuesday that information about lung cancer should be added to the label for Pfizer Inc's (PFE.N) inhaled insulin drug Exubera, due to increased cases in patients taking the product.

The move is no great surprise, since Pfizer and its partner Nektar Therapeutics (NKTR.O) announced in April that clinical trials had revealed a increased cancer rate.

That revelation dealt a final blow to Exubera, which had held the promise of letting diabetics avoid needles but proved a commercial flop. The European agency said Exubera was not expected to be available in the European Union after September 2008. (Reporting by Ben Hirschler; Editing by David Cowell)



More from Reuters

Photo

Fox, Time Warner Cable ink deal to avoid blackout

NEW YORK (Reuters) - Time Warner Cable and News Corp's Fox Networks Group agreed to a brief extension of their current carriage contract late on Thursday to avoid a blackout that would have prevented 13 million U.S. homes from seeing TV shows like "The Simpsons" and "House" as well as college and NFL football games.

» More Top News
A customer is served at a counter inside a foreign exchange store displaying a poster of various banknotes including the Chinese yuan or renminbi (RMB) in Hong Kong November 20, 2009. REUTERS/Bobby Yip
OUTLOOK 2010:

Be careful what you wish for

Pressure on China to loosen its grip on the yuan will continue but the U.S. should tread carefully. Here are five world market issues to watch.  Full Article 

Global Markets
Clients work out on machines at the Bally Total Fitness facility in Arvada, Colorado June 15, 2009. REUTERS/Rick Wilking

Get real with resolutions

We make them and we break them: The secret to keeping them is to avoid the impossible dream.  Full Article 

Lifestyle